MiniMed (Nasdaq:MMED) announced today that it expanded its agreement with Abbott (NYSE:ABT) to add more sensors to its portfolio. The company also announced fourth-quarter earnings results in tandem with the new Abbott integration. MiniMed has an existing partnership with Abbott through a collaboration between the companies agreed in 2024. They integrated Instinct, a sensor made by […]
minimed
MiniMed launches MiniMed Go smart multiple daily injection system in US
MiniMed (Nasdaq:MMED) announced today that it began the U.S. launch of MiniMed Go, a connected smart multiple daily injection (MDI) system. The smart MDI system integrates the InPen smart insulin pen with the Instinct sensor made by Abbott. It all integrates within a mobile app to deliver real-time, personalized insights and actionable guidance. The platform targets people […]
New data backs MiniMed 780G pump, SmartGuard algorithm across CGM types
MiniMed (Nasdaq:MMED) today shared findings from a new randomized crossover study backing the use of its 780 automated insulin pump. Findings demonstrated virtually identical glycemic outcomes for users of the pump across two different continuous glucose monitors (CGMs). Investigators published data today in Diabetes Technology & Therapeutics. MiniMed says outcomes reinforce that its automated insulin […]
MiniMed has a new board member following Brett Wall’s Medtronic departure
MiniMed (Nasdaq:MMED) announced the appointment of Scott Cundy to its board of directors, effective July 3, 2026. Cundy’s appointment comes in the wake of Brett Wall’s departure from MiniMed parent company, Medtronic, announced this week. Wall, the EVP and president of the Medtronic Neuroscience portfolio, served as a class II director for MiniMed and as […]
MiniMed earns Health Canada nod for Simplera Sync sensor with 780G pump for type 2 diabetes
MiniMed (Nasdaq:MMED) announced today that it received approval in Canada for new software for its MiniMed 780G system. Health Canada authorization allows the company to deliver the MiniMed 780G automated insulin delivery system with both its Guardian 4 and Simplera Sync continuous glucose monitor (CGM) sensors. Additionally, the system now has compatibility with Fiasp insulin […]
MiniMed not aware of compromises, doesn’t expect impact from Medtronic cyber breach
MiniMed (Nasdaq:MMED) issued an SEC filing stating that it doesn’t expect to be affected by the recent cybersecurity breach at parent company Medtronic. On April 24, Medtronic issued a statement saying that it determined that an unauthorized party accessed data in certain corporate IT systems. The company identified no impact to products, patient safety, connections to […]
MiniMed flexes with next-gen insulin pump after spinning off from Medtronic
MiniMed Chief Product and Technology Officer Ali Dianaty explains how the former Medtronic Diabetes unit used patient feedback to develop its latest automated insulin delivery innovation.
Within two weeks of MiniMed’s initial public offering in March, the Medtronic spinoff received FDA clearance for its latest-generation MiniMed Flex automated insulin delivery system. The smaller, screenless pump system is a major milestone for one of the world’s largest diabetes businesses. “We have a long history with durable pumps,” MiniMed EVP, Chief Product and Technology Officer, Ali Dianaty said in […]
FDA labels MiniMed insulin pump recall Class II
The FDA recently published a Class II recall related to insulin pump systems made by MiniMed (Nasdaq:MMED). Class II recalls constitute a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. MiniMed is […]
Analysts initiate MiniMed with ‘Buy’ rating in competitive diabetes tech space
BTIG analysts today opened coverage for MiniMed (Nasdaq:MMED) with optimism about the company’s scale, reach and potential pipeline. Marie Thibault, Alexandra Pang and Sam Eiber initiated MiniMed with a “Buy” rating following the Medtronic Diabetes business’ recent initial public offering (IPO), despite the IPO coming up short of its initial target price. “Our MiniMed Group […]
Medtronic cuts 2026 guidance on private equity charge related to MiniMed approval
Medtronic (NYSE:MDT) said in an SEC filing that it lowered its full-year guidance after a one-time charge related to its MiniMed diabetes unit. Last week, MiniMed announced FDA clearance for the MiniMed Flex, a next-generation automated insulin delivery system. Clearance came “several months earlier than anticipated,” according to the filing, facilitating earlier commercialization. R&D for […]
